Magazine Article | June 1, 2021

Companies To Watch: IM Therapeutics

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

IM Therapeutics is an early-stage developer of small molecule oral drugs to treat autoimmune diseases by inhibiting specific HLA (human leukocyte antigen) proteins that help trigger the conditions. Its lead drug, coded IMT-002, is in a Phase 1b trial for treatment of Type 1 diabetes (T1D) by blocking HLA-DQ8, a gene variant that promotes the immune system’s attack on insulin-producing beta cells in the pancreas. The company also has several preclinical lead candidates for a drug to block HLA-DQ2, a gene variant found in 90% of celiac disease. Other early programs have identified candidates for various autoimmune conditions using IM’s proprietary screening technology.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: